Zinnat Tablets 125mg are white,
film-coated, capsule-shaped tablets engraved GXES5 on one side and plain on
the other. Each tablet contains cefuroxime 125mg (as cefuroxime axetil).
Zinnat Tablets 250mg are white,
film-coated, capsule-shaped tablets engraved GXES7 on one side and plain on
the other. Each tablet contains cefuroxime 250mg (as cefuroxime axetil).
Zinnat is an oral prodrug of the
bactericidal cephalosporin antibiotic cefuroxime, which is resistant to most
β-lactamases and is active against a wide range of Gram-positive and
It is indicated for the treatment
of infections caused by sensitive bacteria.
Upper respiratory tract infections for example, ear, nose and throat
infections, such as otitis media, sinusitis, tonsillitis and pharyngitis.
Lower respiratory tract infections for example, pneumonia, acute
bronchitis, and acute exacerbations of chronic bronchitis.
Genito-urinary tract infections for example, pyelonephritis, cystitis
Skin and soft-tissue
infections for example, furunculosis, pyoderma, and impetigo.
uncomplicated gonococcal urethritis and cervicitis.
Cefuroxime is also available as the sodium salt (Zinacef) for parenteral
administration. This permits the use of sequential therapy with the same
antibiotic, when a change from parenteral to oral therapy is clinically
Where appropriate Zinnat is effective when used following initial parenteral
Zinacef (cefuroxime sodium) in the treatment of pneumonia and acute
exacerbations of chronic bronchitis.
Dosage and administration
The usual course of therapy is 7 days (Range 5 - 10 days).
Zinnat should be taken after food for optimum absorption.
Most infections - 250mg twice daily
Urinary tract infections - 125mg
Mild to moderate lower tract
infections e.g. bronchitis - 250mg twice daily
More severe lower tract
infections, or if pneumonia is suspected - 500mg twice daily
Pyelonephritis - 250mg twice
Uncomplicated gonorrhoea - single
dose of 1g
1.5g Zinacef tds or bd (IV or IM) for 48 - 72 hours followed by 500 mg bd
Zinnat (cefuroxime axetil) oral therapy for 7 - 10 days.
Acute exacerbations of chronic bronchitis:
750mg Zinacef tds or bd (IV or IM) for 48 - 72 hours, followed by 500mg bd
Zinnat (cefuroxime axetil) oral therapy for 5 - 10 days.
Duration of both parenteral and oral therapy is determined by the severity
of the infection and the clinical status of the patient.
Most infections - 125mg (1 x 125mg tablet) twice daily, to a maximum of
Children aged two years or older with otitis media or where appropriate,
with more severe infections250mg (1 x 250mg tablet or 2 x 125mg tablets)
twice daily, to a maximum of 500mg daily.
Zinnat Tablets should not be crushed and are therefore unsuitable for
treatment of patients, such as younger children, who cannot swallow tablets.
In children Zinnat Oral suspension may be used.
There is no experience of using Zinnat in children under the age of 3
Patients with known hypersensitivity to cephalosporin antibiotics.
Warnings and precautions
Special care is indicated in patients who have experienced an allergic
reaction to penicillins or other betalactams.
As with other antibiotics, prolonged use of cefuroxime axetil may result in
the overgrowth of nonsusceptible organisms (eg. Candida, Enterococci,
Clostridium difficile), which may require interruption of treatment.
Pseudomembranous colitis has been reported with the use of broad-spectrum
antibiotics, therefore, it is important to consider its diagnosis in
patients who develop serious diarrhoea during or after antibiotic use. With
a sequential therapy regime the timing of change to oral therapy is
determined by the severity of the infection, clinical status of the patient
and susceptibility of the pathogens involved. If there is no clinical
improvement within 72 hours, then the parenteral course of treatment must be
Please refer to the relevant prescribing information for Zinacef before
initiating sequential therapy.
Pregnancy and lactation.
There is no experimental evidence of embryopathic or teratogenic effects
attributable to Zinnat but, as with all drugs, it should be administered
with caution during the early months of pregnancy.
Cefuroxime is excreted in human milk, and consequently caution should be
exercised when Zinnat is administered to a nursing mother.
Effects on ability to drive and operate machinery
Drugs which reduce gastric acidity may result in a lower bioavailability of
Zinnat compared with that of the fasting state and tend to cancel the effect
of enhanced post-prandial absorption.
As a false negative result may occur in the ferricyanide test, it is
recommended that either the glucose oxidase or hexokinase methods are used
to determine blood/plasma glucose levels in patients receiving Zinnat. This
antibiotic does not interfere in the alkaline picrate assay for creatinine.